Important Facts to Know About Hepsera Adefovir Dipivoxil for Hepatitis B Treatment Part 1

Generic Hepsera bearing the generic name Adefovir Dipivoxil was given approval by the US Food and Drug Administration (FDA) in September 2002 for the treatment of continuing and recurrent hepatitis B in adults with indication of active viral reproduction and either indication of relentless rises in serum aminotransferases or histologically dynamic illness. Generic Hepsera, offered as an oral 10 mg pill, is the foremost nucleotide (the fundamental structural unit of nucleic acids, DNA or RNA) analog to be acceptable for this indication.

Mechanism of Action

Generic Hepsera Adefovir Dipivoxil is basically a diester prodrug (inactive or less active form) of Adefovir, which is an open-chain nucleotide analogue of adenosine monophosphate (a nucleotide detected in muscle cells and crucial in metabolic process). Adefovir is metabolized in vivo to the active metabolite, Adefovir diphosphate, by cellular kinases (enzymes that catalyze the transition of a proenzyme to an active enzyme).

Adefovir diphosphate suppresses HBV DNA polymerase, the enzyme responsible for DNA reproduction (reverse transcriptase) by contending with the natural substance deoxyadenosine triphosphate and by inducing DNA chain expiration after its inclusion into viral DNA (according to the prescription label approved by FDA).